Prospective Grant of Exclusive License: Gossypol Acetica Acid for the Treatment of Cancer

Samenvatting

This notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(I) that the National Institutes of Health and Human Services, is contemplating the grant of an exclusive world-wide license to practice the inventions embodied in U.S. Patent No. 5,385,936 and U.S. Patent Application No. 08/379,872 to IVAX Corporation of Miami, Florida. U.S. Patent No. 5,385,936 is directed towards a method of treating cancers using Gossypol Acetic Acid (GAA). U.S. Patent Application No. 08/379,872 is directed towards the use of Gossypol for the treatment of cancer. The patent rights in these inventions have been assigned to the United States of America. This notice revises a previous notice of a prospective grant of exclusive license to Cary Medical Corporation of Great Falls, Virginia for the same technology. See Federal Register, Vol. 61, No. 118, p. 30915-16 (June 18, 1996). The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, NIH receives written evidence and argument that establishes t